2 minute read
Mar. 12, 2022

LY3154885: an Oral D1 Modulator


oral D1 modulator Ph. I candidate for neurological disorders opt. against DDI w/ hepatocyte Cl assay J. Med. Chem. Eli Lilly and Company

Drug Hunter Team

Context. LY3154885 (Eli Lilly and Company) is an oral D1 modulator. Lilly recently completed several clinical trials with LY3154207 ( mevidalen ), the first D1 positive allosteric modulator (D1PAM) with published clinical data, in Parkinson’s disease ( NCT02562768 ), sleep ( NCT02603861 ), and lewy body dementia (LBD) ( NCT03305809 ). In [...]



Other molecules you may be interested in